DATE OF REPORT (Date of earliest event reported): December 5, 2022
(Exact name of registrant as specified in its charter)
(State or other jurisdiction
10 Riverview Dr.
43 Church Street West
Woking, Surrey GU21 6HT
(Address of principal executive offices) (Zip Code)
(Registrant's telephone numbers, including area code)
Check the appropriate box below if the Form 8-Kfiling is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12under the Exchange Act (17 CFR 240.14a-12)
Pre-commencementcommunications pursuant to Rule 14d-2(b)under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencementcommunications pursuant to Rule 13e-4(c)under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Name of each exchange
on which registered
Ordinary shares (€0.001 nominal value per share)
New York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2of the Securities Exchange Act of 1934 (§240.12b-2of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
On December 5, 2022, Linde Inc. (the "Issuer"), a wholly owned subsidiary of Linde plc (the "Company"), issued $300,000,000 aggregate principal amount of 4.800% notes due December 5, 2024 (the "2024 Notes") and $600,000,000 aggregate principal amount of 4.700% notes due December 5, 2025 (the "2025 Notes" and, together with the 2024 Notes, the "Notes"). The Notes are fully and unconditionally guaranteed by the Company, and such guarantee by the Company is guaranteed by Linde GmbH, another wholly owned subsidiary of the Company.
The net proceeds of this offering were approximately $895.6 million, after deducting underwriting discounts, fees and expenses associated with the offering. The Issuer intends to use the net proceeds for general corporate purposes.
In connection with the offering, the Issuer entered into a Terms Agreement dated as of November 28, 2022 (the "Terms Agreement"), among the Issuer, the Company, Linde GmbH, and BofA Securities, Inc., Citigroup Global Markets Inc. and Deutsche Bank Securities Inc., as representatives of the underwriters. The Terms Agreement and the Standard Underwriting Agreement Provisions (June 2, 2020 edition) incorporated by reference in the Terms Agreement are filed as Exhibit 1.1 and 1.2 to this Form 8-K,respectively.
The Notes were issued under an indenture (the "Indenture"), dated as of August 10, 2020, among the Issuer (formerly known as Praxair, Inc.), the Company and U.S. Bank Trust Company, National Association (as successor in interest to U.S. Bank National Association), as trustee. The Indenture, the Form of 2024 Notes with Guarantee Endorsements and the Form of 2025 Notes with Guarantee Endorsements are filed as exhibits to this Form 8-Kand the description of the Indenture contained herein is qualified in its entirety by reference to the Indenture.
This Current Report on Form 8-Kshall not constitute an offer to sell, or the solicitation of an offer to buy, any securities, including any securities of the Company or the Issuer. The foregoing description is qualified in its entirety by reference to the exhibits filed herewith.
Financial Statements and Exhibits.
(d) Exhibit. The following exhibit is filed herewith:
Terms Agreement, dated as of November 28, 2022, among Linde Inc., Linde plc, Linde GmbH, and BofA Securities, Inc., Citigroup Global Markets Inc. and Deutsche Bank Securities Inc., as representatives of the underwriters